Revenue and Profit - For the first quarter of 2022, the company's revenue increased by 16.9% to RMB 7.87 billion compared to RMB 6.73 billion in the same period last year[4]. - Shareholders' profit attributable decreased by 4.6% to RMB 1.40 billion, with basic earnings per share dropping to RMB 11.79 from RMB 12.29[4]. - Excluding fair value changes of financial assets, the basic profit attributable to shareholders increased by 10.3% to RMB 1.54 billion[4]. - The company's profit for the three months ended March 31, 2022, was RMB 1,434,291 thousand, a decrease of 4.2% compared to RMB 1,497,618 thousand for the same period in 2021[11]. - Total comprehensive income for the period was RMB 1,440,455 thousand, down from RMB 1,537,444 thousand year-over-year, reflecting a decline of 6.3%[11]. - The company reported a pre-tax profit of RMB 1,763,922 thousand for the three months ended March 31, 2022, compared to RMB 1,784,045 thousand for the same period in 2021, indicating a slight decrease of 1.1%[12]. - The company’s basic and diluted earnings per share for the three months ended March 31, 2022, were RMB 1,404,519 thousand, compared to RMB 1,471,528 thousand in the same period of 2021, reflecting a decrease of 4.5%[20]. - The company’s total comprehensive income attributable to owners of the company was RMB 1,410,683 thousand for the period, down from RMB 1,511,354 thousand in the previous year, a decline of 6.7%[11]. Pharmaceutical Business Performance - The sales revenue of the pharmaceutical business reached RMB 6.30 billion, a year-on-year increase of 15.0%[5]. - Revenue from pharmaceutical products for the three months ended March 31, 2022, was RMB 6,302,393 thousand, while total revenue was RMB 7,873,893 thousand, showing a year-over-year increase in total revenue[15]. - Vitamin C products generated sales revenue of RMB 700 million, up 33.7% year-on-year, benefiting from increased production capacity[6]. - The functional food and other business saw sales revenue rise by 24.8% to RMB 425 million, driven by increased sales volume and prices of caffeine products[7]. Research and Development - The company submitted 8 international patent applications and obtained 16 patent grants, indicating a strong focus on R&D and innovation[8]. - The company completed the acquisition of 51% of Mingkang Bioengineering Co., which has a significant market potential in thrombolytic therapy[9]. - The company received multiple drug registration approvals, including for innovative drugs targeting various cancers and other conditions[7][8]. Financial Metrics - The gross profit for the first quarter was RMB 5.81 billion, with a gross margin reflecting an increase from the previous year[10]. - The company incurred total depreciation and amortization expenses of RMB 238,994 thousand for the three months ended March 31, 2022, compared to RMB 213,387 thousand in the same period of 2021, representing an increase of 11.9%[19]. - The company reported a foreign exchange gain of RMB 16,413 thousand for the period, compared to a loss of RMB 3,998 thousand in the same period of the previous year[18]. - The weighted average number of ordinary shares used for calculating basic earnings per share was 11,917,035 thousand for the three months ended March 31, 2022, compared to 11,973,770 thousand in the same period of 2021[20]. - The company’s financial data for the three months ended March 31, 2022, was prepared based on internal records and management accounts and has not been reviewed or audited by external auditors[22].
石药集团(01093) - 2022 Q1 - 季度财报